Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Edesa Biotech : Achieves Enrollment Milestone in Phase 2/3 Trial of COVID-19 Monoclonal Antibody Therapy

08/26/2021 | 08:54am EST


© MT Newswires 2021
All news about EDESA BIOTECH, INC.
11/22EDESA BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements and..
AQ
11/04Edesa Biotech Extends COVID-19 Clinical Study to Poland
PU
11/04Edesa Biotech, Inc. Announces Polish Regulators Approves Clinical Trial Application for..
CI
10/19EDESA BIOTECH : Says its COVID-19 Drug Candidate Reduces Mortality, Based on Phase 2 Study..
MT
10/19EDESA BIOTECH : Reports Favorable Mortality Reductions in COVID-19 Study
PU
10/19Edesa Biotech Reports Favorable Mortality Reductions in Covid-19 Study
CI
09/20Top Midday Gainers
MT
09/20Edesa Biotech Sees Positive Results From Study for Covid-19 Treatment
DJ
09/20Top Premarket Gainers
MT
09/20EDESA BIOTECH : Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -15,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,49x
Yield 2021 -
Capitalization 85,8 M 85,8 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 3,50x
Nbr of Employees 12
Free-Float 71,3%
Chart EDESA BIOTECH, INC.
Duration : Period :
Edesa Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDESA BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 6,45 $
Average target price 19,00 $
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Pardeep Nijhawan Chief Executive Officer, Secretary & Director
Michael Brooks President
Kathi Niffenegger Chief Financial Officer
Sean A. MacDonald Chairman
Blair Gordon Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
EDESA BIOTECH, INC.51.76%86
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336